DDInter1394 DDInter1658
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Cholecalciferol
Paricalcitol {u} (Compound) resembles {v} (Compound) Calcitriol
Paricalcitol {u} (Compound) resembles {v} (Compound) Calcipotriol
Paricalcitol {u} may lead to a major life threatening interaction when taken with {v} Dihydrotachysterol
Paricalcitol {u} (Compound) binds {v} (Gene) UGT1A4
Paricalcitol {u} (Compound) palliates {v} (Disease) chronic kidney failure
Paricalcitol {u} (Compound) is included by {v} (Pharmacologic Class) Cholecalciferol
Paricalcitol {u} (Compound) causes {v} (Side Effect) Muscle spasms
Paricalcitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Paricalcitol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Paricalcitol may lead to a major life threatening interaction when taken with Cholecalciferol
Paricalcitol (Compound) resembles Calcitriol (Compound)
Paricalcitol (Compound) resembles Calcipotriol (Compound)
Paricalcitol may lead to a major life threatening interaction when taken with Dihydrotachysterol
Paricalcitol (Compound) binds UGT1A4 (Gene)
Paricalcitol (Compound) palliates chronic kidney failure (Disease)
Paricalcitol (Compound) is included by Cholecalciferol (Pharmacologic Class)
Paricalcitol (Compound) causes Muscle spasms (Side Effect)
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide